Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ociperlimab + tislelizumab versus durvalumab after concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
MOH_2023-01-24_012302Phase 3Completed
- Sponsor
- BeiGene
- Start
- Dec 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Tislelizumab + ociperlimab, Tislelizumab and Durvalumab (3 arms). Started Dec 2022; status: completed.
02
Drugs
ociperlimabtislelizumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2023-01-24_012302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-24_012302.